Clinical Trial

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2025-08-04; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-09-24
Trial Details
NCT Number NCT07115745
Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions Refractory Autoimmune Diseases
Enrollment 125 participants
Start Date 2025-09-04
Primary Completion 2029-03-15 (estimated)
Study Completion 2030-08-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-14